Cellectis (NASDAQ:CLLS) Announces Earnings Results

Cellectis (NASDAQ:CLLS) announced its earnings results on Thursday. The biotechnology company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.04, Zacks reports. Cellectis had a negative net margin of 102.34% and a negative return on equity of 82.92%. The business had revenue of $6.90 million during the quarter, compared to the consensus estimate of $11.05 million.

Cellectis Stock Performance

Shares of NASDAQ:CLLS traded up $0.15 during midday trading on Friday, hitting $2.84. The company had a trading volume of 24,095 shares, compared to its average volume of 16,107. Cellectis has a 12-month low of $2.35 and a 12-month high of $5.48. The company has a market cap of $284.97 million, a price-to-earnings ratio of -4.37 and a beta of 2.91. The company has a fifty day moving average of $2.95 and a two-hundred day moving average of $3.48. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.52 and a quick ratio of 1.52.

Analyst Ratings Changes

CLLS has been the topic of a number of analyst reports. Barclays started coverage on Cellectis in a research report on Thursday, May 28th. They issued an “overweight” rating and a $9.00 price target on the stock. Citizens Jmp reiterated a “market outperform” rating and set a $8.00 price objective on shares of Cellectis in a research note on Tuesday, April 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellectis in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Cellectis currently has a consensus rating of “Moderate Buy” and an average target price of $7.00.

Hedge Funds Weigh In On Cellectis

Hedge funds have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Cellectis by 228.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock worth $5,856,000 after acquiring an additional 3,284,409 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Cellectis in the fourth quarter valued at $15,385,000. Citadel Advisors LLC bought a new stake in Cellectis in the third quarter worth $633,000. Marshall Wace LLP raised its stake in Cellectis by 1,610.3% during the fourth quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after purchasing an additional 168,038 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in Cellectis by 132.9% during the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 26,461 shares during the last quarter. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.